THURSDAY, Sept. 13, 2018 — Lumoxiti injection has been approved to treat certain instances of relapsed or refractory “hairy cell” leukemia (HCL), the U.S. Food and Drug Administration said Thursday. Lumoxiti (moxetumomab pasudotox-tdfk) is among a novel class of drugs called CD22-directed cytotoxins to treat HCL, the agency said. It was approved for adults who […]